Skip to content

Study · Not a test of the peptide alone · 2009

5 results

Determinants of GH-releasing hormone and GH-releasing peptide synergy in men.

Veldhuis JD, Bowers CY

American journal of physiology. Endocrinology and metabolism24 Feb 2009Cited by 7 (Europe PMC)

PMID19240251 (opens in a new tab)PMCIDPMC2681313 (opens in a new tab)DOI10.1152/ajpendo.91001.2008 (opens in a new tab)PepBankPUB-19240251
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

  1. 01HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism

    In men, GH response to combined GHRH and GHRP‑2 infusion (synergy) correlated negatively with age.

    In plain wordsIn men, the GH response to GHRH and GHRP‑2 given together was linked to lower values with older age.

    Peptide
    GHRP-2
    Outcome
    DecreaseCorrelation of GHRH-GHRP synergy with age
    Study

    n = 47

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    GHRH-GHRP synergy correlated negatively with age and AVF (both P < 0.001) and positively with IGF-I (P < 0.001) and IGF-binding protein (IGFBP)-3 (P = 0.031).
    2 context sentences
    Summary · context
    The present strategy was to 1) infuse GHRH and GHRP-2 simultaneously to evoke synergy and 2) downregulate the gonadal axis with leuprolide and then restore placebo (Pl) or testosterone (T) to clamp the sex steroid milieu.
    Summary · context
    Forty-seven men [18-74 yr of age, T = 7-1,950 ng/dl, estradiol (E(2)) = 5-79 pg/ml, insulin-like growth factor (IGF)-I = 115-817 microg/l, AVF = 11-349 cm(2)] were studied.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  2. 02HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism

    In men, GH response to combined GHRH and GHRP‑2 infusion (synergy) correlated negatively with abdominal visceral fat.

    In plain wordsIn men, the GH response to GHRH and GHRP‑2 given together was linked to lower values with more belly fat.

    Peptide
    GHRP-2
    Outcome
    DecreaseCorrelation of GHRH-GHRP synergy with abdominal visceral fat
    Study

    n = 47

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    GHRH-GHRP synergy correlated negatively with age and AVF (both P < 0.001) and positively with IGF-I (P < 0.001) and IGF-binding protein (IGFBP)-3 (P = 0.031).
    2 context sentences
    Summary · context
    The present strategy was to 1) infuse GHRH and GHRP-2 simultaneously to evoke synergy and 2) downregulate the gonadal axis with leuprolide and then restore placebo (Pl) or testosterone (T) to clamp the sex steroid milieu.
    Summary · context
    Forty-seven men [18-74 yr of age, T = 7-1,950 ng/dl, estradiol (E(2)) = 5-79 pg/ml, insulin-like growth factor (IGF)-I = 115-817 microg/l, AVF = 11-349 cm(2)] were studied.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  3. 03HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism

    In men, GH response to combined GHRH and GHRP‑2 infusion (synergy) correlated positively with IGF-I.

    In plain wordsIn men, the GH response to GHRH and GHRP‑2 given together was linked to higher values with higher IGF-I.

    Peptide
    GHRP-2
    Outcome
    IncreaseCorrelation of GHRH-GHRP synergy with IGF-I
    Study

    n = 47

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    GHRH-GHRP synergy correlated negatively with age and AVF (both P < 0.001) and positively with IGF-I (P < 0.001) and IGF-binding protein (IGFBP)-3 (P = 0.031).
    2 context sentences
    Summary · context
    The present strategy was to 1) infuse GHRH and GHRP-2 simultaneously to evoke synergy and 2) downregulate the gonadal axis with leuprolide and then restore placebo (Pl) or testosterone (T) to clamp the sex steroid milieu.
    Summary · context
    Forty-seven men [18-74 yr of age, T = 7-1,950 ng/dl, estradiol (E(2)) = 5-79 pg/ml, insulin-like growth factor (IGF)-I = 115-817 microg/l, AVF = 11-349 cm(2)] were studied.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  4. 04HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism

    In men, GH response to combined GHRH and GHRP‑2 infusion (synergy) correlated positively with IGFBP-3.

    In plain wordsIn men, the GH response to GHRH and GHRP‑2 given together was linked to higher values with higher IGFBP-3.

    Peptide
    GHRP-2
    Outcome
    IncreaseCorrelation of GHRH-GHRP synergy with IGFBP-3
    Study

    n = 47

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    GHRH-GHRP synergy correlated negatively with age and AVF (both P < 0.001) and positively with IGF-I (P < 0.001) and IGF-binding protein (IGFBP)-3 (P = 0.031).
    2 context sentences
    Summary · context
    The present strategy was to 1) infuse GHRH and GHRP-2 simultaneously to evoke synergy and 2) downregulate the gonadal axis with leuprolide and then restore placebo (Pl) or testosterone (T) to clamp the sex steroid milieu.
    Summary · context
    Forty-seven men [18-74 yr of age, T = 7-1,950 ng/dl, estradiol (E(2)) = 5-79 pg/ml, insulin-like growth factor (IGF)-I = 115-817 microg/l, AVF = 11-349 cm(2)] were studied.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  5. 05HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism

    In men, abdominal visceral fat, IGF-I and IGFBP-3 together explained 60% of the variability in GHRH-GHRP synergy (P < 0.001).

    In plain wordsIn men, belly fat, IGF-I and IGFBP-3 together explained most of the difference in the GH response to GHRH and GHRP‑2 given together.

    Peptide
    GHRP-2
    Outcome
    Not applicableVariability of GHRH-GHRP synergy explained by AVF, IGF-I and IGFBP-3
    Study

    n = 47

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Variability explained
    60%
    AVF, IGF-I and IGFBP-3 together

    Source sentences

    Summary
    AVF, IGF-I, and IGFBP-3 together explained 60% of the variability in GHRH-GHRP synergy (P < 0.001)
    2 context sentences
    Summary · context
    The present strategy was to 1) infuse GHRH and GHRP-2 simultaneously to evoke synergy and 2) downregulate the gonadal axis with leuprolide and then restore placebo (Pl) or testosterone (T) to clamp the sex steroid milieu.
    Summary · context
    Forty-seven men [18-74 yr of age, T = 7-1,950 ng/dl, estradiol (E(2)) = 5-79 pg/ml, insulin-like growth factor (IGF)-I = 115-817 microg/l, AVF = 11-349 cm(2)] were studied.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.